UNIVERSITAS GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Abdelhamid, E., Awad, A. and Gismallah, A. 2008, Evaluation of a Hospital Pharmacy-Based Pharmaceutical Care Services for Asthma Patients, *Pharmacy Practice*, **6(1)**:25-32.

Adams, J.Y., Sutter, M.E., Albertson, T.E. 2011, The Patient with Asthma in the Emergency Department. Clinical Reviews in Allergy & Immunology, *Springer Science+Business Media, LLC*, **43(1)**:14-29.

Alington, S., Beasley, R. 2007, Asthma exacerbations·5: Assessment and Management of Severe Asthma in Adults in Hospital, *Thorax*. **62(5):** 447–458.

Alsagaff, H., Mukty, A., 2002, *Dasar-Dasar Ilmu Penyakit Paru*, Airlangga University Press, Surabaya.

American Academy of Allergy, Asthma & Immunology. 2013, *Peak Flow Meter: Tips to Remember*, **viewed 1 January 2013 <http://www.aaaai.org/conditions-and-treatments/library/at-a-glance/peak-flow-meter.aspx>.**

American Lung Association. 2015. Lung Health & Disease: Measuring Your Peak Flow Rate, viewed 1 December 2015 **<http://www.lung.org/lung-health-and-diseases/lung-disease-lookup/asthma/living-with-asthma/managing-asthma/measuring-your-peak-flow rate.html?referrer=https://www.google.co.id/>.**

American Society of Hospital Pharmacists. 1995, ASHP Guidelines on Adverse Drug Reaction Monitoring and Reporting, *American Journal Health-System Pharmacy*, **52(4)**:417-9.

American Society of Health-System Pharmacists. 1996, ASHP Guidelines on a Standardized Method for Pharmaceutical Care, *Am J Health-Syst Pharm*, **53**:1713–6.

American Thoracic Society. 2015. *What Is Theophylline/Theofylline?* , viewed 1 December 2015 (http://www.thoracic.org/copd-guidelines/for-patients/what-kind-of-medications-are-there-for-copd/what-is-theophylline-theofylline.php)

Amodio, P., Lauro, S., Rondana, M., Crema, G. 1991, Theophylline pharmacokinetics and liver function indexes in chronic liver disease, *Respiration*, **58(2)**:106111.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Anbar, R.D. 2012, *Functional Respiratory Disorders: When Respiratory Symptoms Do Not Respond to Pulmonary Treatment*. 1st Ed. USA: Human Press. P.185.

Anderson, P.O., Knoben, J.E. and Troutman, W.G. 2002, *Handbook of Clinical Drug Data*, 10th edition, McGraw-Hill Companies, New York. US.

Arianti, E. 2009, Analisis Drugs Related Problems pada Pasien Asma Usia Dewasa di Rumah Sakit Siti Khodijah Sepanjang- Sidoarjo selama Januari-Desember 2008, *Skripsi*, S.Farm., Fakultas Farmasi Universitas Surabaya, Surabaya.

Arnold, R.J.G. 2010, *Pharmacoeconomics: From theory to Practice*, CRC Press. US.

Aryani, E., Suherman, J. 2009, Pengaruh Ukuran Manset Terhadap Hasil Pengukuran Tekanan Darah. *JKM*, **9(1)**:50-53.

Aslaksen, A., Bakke, O.M. and Vigander, T. 1981, Comparative Pharmacokinetics of Theophylline and Aminophylline in Man, *British Journal Clinical Pharmacologi*, **11**:269-273.

Asthma Management Handbook. 2006, *National Asthma Council Australia*.

Baba, K. and Yamaguchi, E. 2005, Issues Associated with Stepwise Management of Bronchial Asthma, *Allergology International*, **54**:203-208.

Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. 2007. *Pedoman Pengukuran dan Pemeriksaan*, Jakarta., Depkes RI.

Badan Pengawas Obat dan Makanan (BPOM), 2012. *Formulir Pelaporan Efek Samping Obat: Algoritme Naranjo*.

Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan Republik Indonesia. 2008. *Riset Kesehatan Dasar* (RISKESDAS) 2007.

Barnard, A. 2005, Management of an Acute Asthma Attack, *Australian Family Physician*, **34(7)**:531-534.

Barnes, P.J. and Pauwels, R.A. 1994, Theophylline in the Management of Asthma: time for reappraisal?, *European Respiratory Journal*, **7**:579-591.

Barnes, P.J. 2003, Theophylline-New Perspective for an Old Drug, *American Journal of Respiratory and Critical Care Medicine*, **167**:813-818.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Barnes, P.J., Drazen, J.M., Lennard, S.I. 2009. *Asthma and COPD: Basic Mechanisms and Clinical Management*. 2nd ed. Elsevier Ltd. USA. P.20-21.

Barnes, P.J. 2010, Theophylline, *Pharmaceuticals (Basel)*, **3(3)**:725–747.

Basvi, P.T., Dandara, C., Bapiro, T.E., Hasler, A.J. 2007, Role of CYP1A2*1F on CYP1A2 activity in a black African population as determined by caffeine phenotyping. *Journal of Chinese Clinical Medicine*, **2(4)**:211–214.

Bauer, L.A., Bauer, S.P., Blouin, R.A. 1982, The Effect of Acute and Chronic Renal Failure on Theophylline Clearance, *J.Clin Pharmacol*, **22(1)**:65-68.

Baxter, K. 2008. *Stockley's Drug Interactions*, 8th ed. Pharmaceutical Press. UK. P.1183.

Berger, M.L., Bingefors, K., Hedblom, E.C., Pashos, C.L. and Torrance, G.W. 2003, *Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms*, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Book of Term, Lawrenceville , US.

Beevers, G., Lip, G.Y.H., o'Brien, E. 2001. ABC of hypertension Blood pressure measurement Part I—Sphygmomanometry: factors common to all techniques. *British Medicine Journal*, **322**:981-985.

Blix, H., Vitkil, K., Asmund, R., Tron, M., Bodil, H. and Piia, P., *et al*. 2004, The Majority of Hospitalised Patients Have Drug-Related Problems: Result from A Prospective Study in General Hospitals, *European Journal of Clinical Pharmacology*, **60(9)**:651-8.

Bootman, J.L. and Harrison, D.L. 1997, Pharmacoeconomics: Basic Concepts and Terminology, *British and Journal Clinical Pharmacology*, **43**:343–348.

Bootman, J.L., Townsend, R.J. and McGhan, W.F. 2005, *Principles of Pharmacoeconomics*, 3rd edition, Harvey Whitney Books Company. US.

Bootman, J.L. 2007, *Drug Related Morbidity and Mortality Impact of Pharmaceutical Care*. *World Health Organization: Essensial Medicines and Policy Department (EDM): International Conferences on Improving Use of Medicines (ICIUM).*

Bittar, G., Friedman, H.S., 1991, The Arrhymogenicity of Theophylline A Multivariate Analysis of Clinical Determinats, *CHEST*, **(99):**1415-1420.

Briggs, G.G., Freeman, R.K., Yaffe, S.J., 2011. *Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk*. 9th ed. Lippincott Williams & Wilkins. Philadelphia. p.1427.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Bruyne, M.C., Kors, J.A., Hoes, A.W., Klootwijk, P., *et al*. 1999, Both Decreased and Increased Heart Rate Variability on the Standard 10-Second Electrocardiogram Predict Cardiac Mortality In the Elderly, *American Journal of Epidemiology*, **150(12):**1282-1288.

Burki, N.K. 1997, The effects of the combination of inhaled ipratropium and oral theophylline in asthma, *CHEST*, **111**:1509–13.

Caffarelli, C., Deriu, F.M., Terzi, V. *et al.*, 2000, Gastrointestinal Symptoms in Patients Asthma, *Archives of Disease in Childhood*, **82**:131–135.

Camargo, C.A., Rachelefsky, G., Schatz, M. 2009, Managing Asthma Exacerbations in the Emergency Department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 Guidelines for the Management of Asthma Exacerbations, *Proceeding of the American Thoracic Society*, **6**:357-366.

Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 1997, *Guidelines for Economic Evaluation of Pharmaceuticals*.

Cairns, C.B. 2006, Acute Asthma Exacerbations: Phenotypes and Management, *Clinical in Chest Medicine*, **27**:99-108.

Cazzola, M., Matera, M.G. 2012, Tremor and b2-adrenergic agents: Is it a real clinical problem? *Pulmonary Pharmacology & Therapeutics*,**25**:4-10.

Centers for Disease Control and Prevention. 2013, Asthma Facts—CDC's National Asthma Control Program Grantees. Atlanta, GA: U.S. Department of Health and Human Services, *Centers for Disease Control and Prevention*.

Cevik, Y., Kavalci, C., Das, M., Izdes, S. 2010, Severe Theophylline Intoxication, Rhabdomyolysis, Disseminated Intravascular Coagulopathy And Death: Case Report. *Akademik Acil Tıp Olgu Sunumları Dergisi*, **1(1)**:24-27.

Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., Kamataki, T. 1999, Detection of three genetic polymorphisms in the 5′-flanking region and intron I of human CYP1A2 in the Japanese population, *Jpn J Cancer Res*. **90**:899–902.

Chipps, B.E., Foggs, M.B. 2015, Asthma Management and the Allergist: Better Outcomes at Lower Cost, *American College of Allergy*.

Choi, I.S. 2011. Gender-Specific Asthma Treatment. *Allergy, Asthma & Immunology Research*, **3(2)**:74-80.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Chung, K.F., Dent, G., Barnes, P.J. 1989, Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man. *Thorax*, **44(2)**:102-7.

Cohn JN, Kowey PR, Whelton PK, Prisant LM., 2000, New Guidelines for potassium Replacement in Clinical Practice. Arch Intern Med, **160**:2429-2436.

College voor Zorgverzerkeringen. 2006, ***Guidelines for Pharmacoeconomic Research, Updated Version*****.** Diemen, The Netherlands: College voor Zorgverzekeringen (CVZ).

Corelli, R.L., Kradjan, W.A., Koda-Kimble, M.A., Young, L.Y., Guglielmo, B.J. and Alldredge, B.K. 2009, A*ssessment of Therapy and Pharmaceutical Care*, in in Koda-Kimble, M. A., Young, L.Y., Kradjan, W.A., Guglielmo, B.J., Alldredge, B.K. and Corelli, R.L. *Applied Therapeutics – The Clinical Use of Drugs*, 9th edition, Lippincort Williams&Wilkins, Philadelphia. US. pp 1.1-1.21.

Crawford, P., Zimmerman, E.E., 2011, Differentiation and Diagnosis of Tremor. *American Family Physician*, **83(6)**:697-702.

Dall'Igna, O.P., Porciúncula, L.O., Souza, D.O., Cunha, R.A., Lara, D.R. 2003, Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity, *British Journal of Pharmacology*, **138(7)**:1207-1209.

Dash, A., Agrawal, A., Venkat, N., Moxham, J., Ponte, J. 1994, Effect of oral theophylline on resting energy expenditure in normal volunteers, *Thorax,* **49**:1116-1120.

Davies, E.C., Rowe, P.H., James, S., Nickless, G., Ganguli, A. and Danjuma, M., *et al*. 2011, An Investigation of Disagreement in Causality Assessment of Adverse Drug Reactions, *Pharmaceutical Medicine*, **25(1)**:17-24.

Davies. B., Brooks, G., Devoy, M. 1998, The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies, Respiratory Medicine, 92(2):256–263.

Dawson, K.P., Fergusson, D.M., 1982, Effects of oral theophylline and oral salbutamol in the treatment of asthma, *Archives of Disease in Childhood*, **57**:674-676.

Departemen Kesehatan RI. 2009, *Pedoman Pengendalian Penyakit Asma*, Direktorat Jenderal PP & PL Departemen Kesehatan, Jakarta. Indonesia.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Dougherty, R.H., Fahy, J.V. 2009, Acute Exacerbations of Asthma: Epidemiology, Biology and the Exacerbation-Prone Phenotype, *Clin Exp Allergy*, **39(2):** 193–202.

Elble, R., Bain, P., Forjaz, M.J., Haubenberger, D., Testa, C., *et al*. 2013, Task Force Report: Scales for Screening and Evaluating Tremor, *Movement Disorders*, **28(13)**:1793-1800.

Elble, R., LeWitt, P., Lyons, K., Ondo, W., Pahwa, R., Sethi, K., Stover, N., Tarsy, D., Testa, C., Tintner, R., Zesiewicz, T. 2012, Reliability of The Essential Tremor Rating Assessment Scale (TETRAS). *Movement* Disorders, **27(1)**:1241.

Eltonsy, S., Forget, A., Blais, L. 2011. Beta2-agonists Use During Pregnancy and the Risk of Congenital Malformations, *Birth Defects Rs A Clin Mol Teratol*., **91(11)**:937-47.

Eskandari, N., Wickramasinghe, T. and Peachell, P.T. 2004, Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils, *British Journal of Pharmacology*, **142**:1265–1272.

European Medicines Agency. 2001, *ICH Topic S 7 A: Safety Pharmacology Studies for Human Pharmaceuticals: Note for Guidance on Safety Pharmacology Studies for Human Pharmaceuticals* (CPMP/ICH/539/00).

Ezeamuzie, C.I. and Shihab, P.K. 2010, Interactions between Theophylline and Salbutamol on Cytokine Release in Human Monocytes, *The Journal of Pharmacology and Experimental Therapeutics*, **334(1)**:302-309.

European Society of Hypertension–European Society of Cardiology. 2013, Guidelines for the Management of Arterial Hypertension. *Journal Hypertension*, **31**:1281–1357.

Fal, A.M. and Rosiek-Biegus, M. 2011, *Pharmacogenetics of Asthma*, in Sanoudou D, *Clinical Applications of Pharmacogenetics*, InTech. Kroatia. pp183-200.

Fenech, A.G. and Grech, G. 2011, Pharmacogenetics: Where do we stand?, *Journal of the Malta College of Pharmacy Practice*, **11**:25-33.

Fernandez, E., Perez, R., Hernandez, A., Tejada, P., *et al*. 2011, Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults, *Pharmaceutics* 2011, ***3*(1)**, 53-72

Fong, N. 2011, *Aminophylline/Theophylline: Loading and maintenance dose*, NHS Trust: East Lancashire Hospitals.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Fotinos, C. and Dodson, S. 2002, Is there a role for theophylline in treating patients with asthma?, *Family Practice Inquiries Network*, **51(9)**.

Fukami, T., Nakajima, M., Sakai, H., Katoh, M. and Yokoi, T. 2007, Short Communication: CYP2A13 Metabolizes the Substrates of Human CYP1A2, Phenacetin, and Theophylline, *Drug Metabolism and Disposition*, **35(3)**:335–339.

Guidelines and Audit Implementation Network (GAIN). 2008, Guidelines for the Treatment of Hyperkalaemia in Adults. Ireland.

Gazdik, F., Hrmova, A. and Gazdikova, K. 2001, Pharmacoecomy of Adult Asthmatics, *Bratisl Lek Listy*, **102(12)**:575-580.

Ghiculescu, R.A. 2008, Therapeutic drug monitoring: which drugs, why, when and how to do it, *Australian Prescriber*, **31(2)**:42–44.

Global Initiative for Asthma (GINA), 2015, *Global Strategy for Asthma Management & Prevention* (Update).

Global Initiative for Chronic Obstructive (GOLD). 2014. *Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease* (Update).

Golan, D.E., Tashjian, A.H., Armstrong, E.J., Armstrong, A.W. 2008. *Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy*. 2nd ed. Lippincott Williams & Wilkins. Philadelphia. p340 & 833.

Goldstein, M.F. dan Chervinsky, P. 2002, Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma -- a double-blind randomized placebo-controlled multicentre clinical trial, *Medical Science Monitor*, **8(4)**:CR297-304.

Groggins, R.C., Lenney, W., Milner, A.D., Stokes, G.M. 1980. Efficacy of orally administered salbutamol and theophylline in pre-schoolchildren with asthma. *Archives of Disease in Childhood*, **55**:204-206.

Gunes, A., Ozbey, G., Vural, E.H., Uluoglu, C., Scordo, M.G. and Zengil, H., *et al.* 2009, Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population, *Pharmacogenomics*, **10(5)**:769-78.

Guo, J.J., Pandey, A., Doyle, J., Bian, B., Lis, Y. and Raisch, D. 2010, A Review of Quantitative Risk-Benefit Methodologies for Assessing Drug Safety and Efficacy- Report of the ISPOR Risk-Benenfit Management Working Group,

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

International Society for Pharmacoeconomics and Outcomes Research (ISPOR), **13(5)**:657-666.

Hambleton, G. and Stone, M.J. 1979, Comparison of IV salbutamol with IV aminophylline in the treatment of severe, *Acute Asthma in Childhood*, *Archives of Disease in Childhood*, **54**:391-402.

Hamdy, S. I., Hiratsuka, M., Narahara, K., Endo, N., El-Enany, M., Moursi, N., Ahmed, M. dan Mizugaki, M. 2003, Genotyping of Four Polymorphisms in The CYP1A2 Gene in The Egyptian Population, *British Journal of Clinical Parmacology*, **55**: 321-324

Harris, A.D., McGregor, J.C., Perencevich, E.N., Furuno, F.P., *et al*., 2006. The Use and Interpretation of Quasi-Experimental Studies in Medical Informatics, *Journal of the American Medical Informatics Association* (JAMIA), **13(1)**: 16–23.

Hart, S.P. 2000, Should Aminophylline be Abandoned in the The Treatment of Acute Asthma in Adults?. *Q J Med*, **93**:761-765.

Hartnett, B.J.S., Marlin, G.E. 1976, Comparison of oral theophylline and salbutamol by inhalation in asthmatic patients, *Br J Clin Pharmacol*., **3(4)**:591–594.

Harver, R.A., Champe, P.C., Finkel, R., Cubeddu, L.X. and Clark, M.A. 2009, *Pharmacology*, 4th edition, Lippincott Williams and Wilkins, Philadelphia, US. pp 68-70.

Health and Safety Authority, 2008. *Guidelines on Occupational Asthma* (online) , VIEWED 1 January 2013, <http://www.hsa.ie/eng/Publications_and_Forms/Publications/Occupational_Health/Guidelines_on_Occupational_Asthma.pdf>.

Hedqvist, P., Fredholm, B.B., Olundh, S. 1978, Antagonistic Effects of Theophylline and Adenosine on Adrenergic Neuroeffector Transmission in The Rabbit Kidney, *Departement of Physiology and Pharmacology*, **43 (4)**: 592-598

Hess, C.W., Pullman, S.L., 2012. Tremor: Clinical Phenomenology and Assessment Techniques. Tremor Phenomenology and Assessment, *Tremor, Other Hyperkinet Mov* (N Y). 2012; 2: tre-02-65-365-1.

Higgins, B.G., Britton, J.R., Chinn, S., Lai, K.K., *et al*. 1993, Factors affecting peak expiratory flow variability and bronchial reactivity in a random population sample, Thorax, **48**:899-905.

UNIVERSITAS GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Huang, L., Bao, Y., Xu, Z., Lei, X., *et al*. 2013, Neonatal bilirubin levels and childhood asthma in the US Collaborative Perinatal Project, 1959-1965. *Am J Epidemiol.*, **178(12)**:1691-7.

Hubeiz, A.A. 1983, Teofilina: Studi Eksperimental Profil Farmakokinetik, *Disertasi*, Dr., Fakultas Farmasi Universitas Airlangga, Surabaya.

Hudson, O.H. 2013, *Drug Information Handbook: A Comprehensive Resource for all Clinicians and Healthcare Professionals*, 22th edition, Lexi-Comp Inc, Hudson. US.

Hung, C.H., Chu, D.M., Wang, C.L., Yang, K.D. 1999, Hypokalemia and salbutamol therapy in asthma, *Pediatric Pulmonology*, **27(1)**:27 - 31.

Hussein, R.M., Elsirafy, O.M., Wahba, Y.S., Kawy, H.S. *et al*. 2015, Theophylline, an old drug with multi-faceted effects: Its potential benefits in immunological liver injury in rats, *Life Sci*, **136**:100-7.

Hymel, G., Tarabar, A**.** and **VanDeVoort, J.T.** 2011, Theophylline Toxicity in Emergency Medicine, *Medscape Reference*, *WebMD LLC*, VIEWED 1 January 2013, <http://emedicine.medscape.com/article/818847-overview>.

ICH Harmonised Tripartite Guideline. 1995, *ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Note for Guidance on Clinical Safety Data Management: Definitions* and Standards for Expedited Reporting (CPMP/ICH/377/95).

ICH Harmonised Tripartite Guideline (PHARMACOVIGILANCE PLANNING E2E). 2004, *International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Expert Working Group*.

Idrus, I. S., Yunus, F., Andarini, S. L., Setiawati, A., 2012, Perbandingan Efek Salbutamol dengan Salbutamol yang Diencerkan dengan NaCl 0,9% pada Pasien Dewasa dengan Asma Akut Sedang di RS Persahabatan, Jakarta, *J Respir Indo*, **32(3)**:167-176.

Ikawati Z, 2008, *farmakoterapi penyakit system pernafasan*, Pustaka Adipura Yogyakarta, 37.

Institute for Health Metrics and Evaluation. 2013, *Global Burden of Disease, Visualizations, GBD Arrow Diagram*. VIEWED 12 February 2013, <http://www.healthmetricsandevaluation.org/gbd/visualizations/gbd-arrow-diagram>.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Iribarren, C., Sidney, S., Lydick, E., Sorel, M.E. 2001, The association between asthma, asthma therapeutic classes and hepatic enzyme elevation among adult HMO members, *Comprehensive Therapy*, **27(2)**:133-139.

Iribarren, C., Tolstykh, I.V., Miller, M.K., Sobel, E., Eisner, M.D. 2012. Adult asthma and risk of coronary heart disease, cerebrovascular disease, and heart failure: a prospective study of 2 matched cohorts, *Am J Epidemiol*, **176(11)**:1014-1024.

Izeboud, C.A., Hoebe, K.H., Grootendors,t A.F., Nijmeijer, S.M., *et al*. 2004. Endotoxin-induced liver damage in rats is minimized by beta 2-adrenoceptor stimulation. *Inflamm Res*, **53(3)**:93-9.

Jackson, D.J., Sykes, A., Mallia, P., Johnston, S.L. 2011, Asthma Exacerbations: Origin, effect, and Prevention, *Journal of Allergy Clinical Immunology*, **128**:1165-74.

Jain, S.K., Kumar, R., Sharma, D.A. 1983, Factors Influencing Peak Expiratory Flow Rate (PEFR) In Normal Subjects – II, *Lugn India*, **1(3)**:92-97.

Jin, C., Ding, S.L., Lin, S.C., 2012, Phosphodiesterase 4 and Its Inhibitors in Inflammatory Diseases, *Chang Gung Med J*, **35(3)**:197-210.

Junaidi, C.,Y. 2006, Pola Penggunaan Obat pada Penderita Asma Bronchiale yang Menjalani Rawat Inap di RSK St. Vincentius A Paulo selama Tahun 2004, *Skripsi*, S.Farm., Fakultas Farmasi Universitas Surabaya, Surabaya.

Kamath, M.V., Watanabe, M.A., Upton, A.R.M. 2012. *Heart Rate Variability (HRV) Signal Analysis: Clinical Applications*. CRC Press. Perancis. P253.

Katzung, B. (Ed.). 2012, *Basic and Clinial Pharmacology*, 12th edition, McGraw-Hill Medical, New York. US.chapter.20

KDIGO (Kidney Disease Improving Global Outcomes). 2012, KDIGO Clinical Practice Guideline for Acute Kidney Injur, *Kidney International Supplements*, **2(1)**:59.

Keene, D.L., Melmed, C.A., Andermamn, F., Baxter, D.W. 1981, Anoxic tonic seizures due to asthma; a serious complication in adults, *Can J Neurol Sci*, **8(2)**:177-9.

Kelly, H.W. and Sorkness, C. 2011, Asthma, in DiPiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B. and Posey, M., editors, *Pharmacotherapy: A Pathophysiologic Approach*, 8th edition, McGrawHill, New York. US.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Kementrian Kesehatan. 2015, *Keputusan Menteri Kesehatan Republik Indonesia*, *Nomor 312/MENKES/SK/IX/2015*, *tentang Daftar Obat Essensial 2015*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Kementrian Kesehatan. 2015, *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/523/2015*, *tentang Formularium Nasional*, Jakarta, Kementerian Kesehatan Republik Indonesia.

Kendall, J.M. 2003, *Designing a research project: randomised controlled trials and their principles*, *Emergency Medical Journal*, **20**:164–168.

Kruuse, C., Thomsen, L.L., Jacobsen, T.B., Olesen, J. 2002, The Phosphodiesterase 5 Inhibitor Sildenafil Has No Effect on Cerebral Blood Flow or Blood Velocity, but Nevertheless Induces Headache in Healthy Subjects, *Journal of Cerebral Blood Flow & Metabolism,* **22(9)**:1124–1131.

Kuntz, H.D., Straub, H., May, B. 1983, Theophylline Elimination in Congestive Heart Failure, *Klinische Wochenschrift*, **61(21)**:1105-1106.

Kurth, J.H. 2000, Pharmacogenomics: Future Promise Of A Tool For Identifying Patients At Risk, *Drug Information Journal*, **34**:223–227.

Laban RB, Mclntyre CM, Christenson JM, et al., 2006, Aminophylline in Bradyasystolic Cardiac Arrest: A Randomized Placebo-Controlled Trial, *Lancet*, **367(9522)**:1577-1584.

Lakshmi, A., Lakshmanan, A., Kumar, G., Saravanan,A. 2014, Effect of Intensity of Cigarette Smoking on Haematological and Lipid Parameters, *J Clin Diagn Res*. **8(7)**:BC11–BC13.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Landells, L.J., Jensen, M.W., Orr, L.M., Spina, D., Connor, B.J.O. and Page, C.P. 2000, The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear cells from healthy and asthmatic subjects, *British Journal of Pharmacology*, **129(6)**:1140–1144.

Lahrmann, H., Cortelli, P., Hilz, M., Mathias, C.J., Struhal, W., Tassinari, M.. Orthostatic hypotension. In: Gilhus NE, Barnes MP, Brainin M, editor(s). European handbook of neurological management. 2nd ed. Vol. 1. Oxford (UK): Wiley-Blackwell; 2011. p. 469-75.

Lee, T.A., Schumock, G.T., Bartle, B. and Pickard, A.S. 2009, Mortality Risk in Chronic Obstructive Pulmonary Disease Patients using Theophylline, *Pharmacotherapy*, **29(9)**:1039-53.

Lessard, A., Turcotte, H., Cormier, Y., Boulet, L.P. 2008, Obesity & Asthma: A Specific Phenotype?, *CHEST*, **134(2)**:317-323.

Lim, J. S. L., Singh, O., Ramasamy, R. D., Ramasamy, S., Subramanian, K., Lee, E. dan Chowbay, B. 2010, Pharmacogenetics of CYP1A2, Novel Polymorphisms and Haplotypes in Three Distinct Asian Populations, *Drug Metab. Pahrmacokinet*, **25(6)**:616-623

Lima, J.J., Blake, K.V., Tantisira, K.G. and Weiss, S.T. 2009, Pharmacogenetics of Asthma, *Curr Opin Pulm Med*, **15(1)**:57-62.

Link SM, 2012, Evaluation and Initial Treatment of Supraventricular Tachycardia, *The New England Journal of Medicine*, **367**:1438-1448.

Litbang Depkes RI, 2007. *Pedoman Pengambilan, Penyimpanan, Pengemasan Dan Pengiriman Spesimen Darah*. Jakarta: Media Litbang. P6-7

Littenberg, B. 1988, Aminophylline Treatment in Severe, Acute Asthma a Meta-analysis. *Journal of the American Medical Association* (*JAMA)*, **259(11)**:1678-1684.

Lorensia, A., Wahjuningsih, E., Canggih, B., Lisiska, N. 2011, Pharmacist's Strategies in Treating Asthma Bronchiale Outpatient, *Jurnal of Tropical Pharmacy and Chemistry* (UNMUL), **1(3)**:177-191

Lorensia, A., Wahjuningsih, E., Supriadi, 2012, Keamanan Penggunaan Aminophylline pada Asma di Rumah Sakit Delta Surya Sidoarjo, *Indonesia journal of Clinical Pharmacy* (IJCP), **1(4)**:154-161

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Lorensia, A., Canggih, B., Wijaya, R.I., 2013[a], Analisa Adverse Drug Reactions pada Pasien Asma di Suatu Rumah Sakit, Surabaya, *Jurnal Farmasi Indonesia*, **6(3)**:142-150

Lorensia, A., Wijaya, R.I., Canggih, B., 2013[b], Studi Efektifitas Biaya terkait Pemilihan Obat Asma Bronkiale Rawat Inap di Suatu Rumah Sakit Swasta di Surabaya, *Jurnal Ilmiah Sains & Teknologi*, **7(1)**:56-63

Lorensia, A., Amalia, R.A., 2015, Studi Farmakovigilans Pengobatan Asma pada Pasien Rawat Inap di suatu Rumah Sakit di Bojonegoro, *Jurnal Ilmiah Manuntung* (JIM), **1(1)**:8-18

Lugogo, N.L. and MacIntyre, N.R. 2008, Life-Threatening Asthma: Pathophysiology and Management, *Respiratory Care*, **53(6)**:726-739

Madanick, R.D. 2013, Management of GERD-Related Chronic Cough. *Gastroenterol Hepatol*, **9(5)**:311–313.

Makino, S., Adachi, M., Ohta, K., Kihara, N., Nakajima, S., Nishima, S., *et al*. 2006, A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD, *Allergol Int*, **55(4)**:395-402.

Mally, J., Stone, T.W. 1990, The effect of theophylline on essential tremor: The possible role of GABA, *Pharmacology Biochemistry and Behavior*, **39(2)**:345-349.

Mangunrejo, H., Widjaja, A., Kusumo, D., Sutoyo, Yunus, F. And Pradjnaporamita, *et al*. 2004, *Pedoman Diagnosis dan Penatalaksanaan di Indonesia: Asma*, Perhimpunan Dokter Paru Indonesia.

Marieb, EN, 2006, *Essential of Human Anatomy & Physiology*, 10th edition, The Benyamin/Cummings Publishing Company, Inc, California.

Mark, W.J., 2005, *Appendix H Fahn-Tolosa-Marin Tremor Rating*. In Deep Brain Stimulation Management. 2nd edition. Cambridge University Press. Pp.213-215.

Mathur, S., Khalid, I., Pesola, G. 2012, Beta Agonist-Induced Lactic Acidosis in Asthma. The Internet Journal of Asthma, *Allergy and Immunology*, **8(1)**:1-3.

McCrum-Gardner, E. 2010, Sample size and power calculations made simple. *International Journal of Therapy and Rehabilitation*, **17(1)**:10-14.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

McEvoy G, Snow E, Miller J, *et al*., 2008, American Society of Health System Pharmacists, Bethesda.

Milani, G.K., Filho, N.A.R., Riedi, C.A., Figueiredo, B.C. 2004, Nebulized budesonide to treat acute asthma in children, *Journal de Pediatria*, **80(2)**:106-112.

Michel, D.J. and Knodel, L.C. 1986, Comparison of three algorithms used to evaluate adverse drug reactions, *American Journal of Health-System Pharmacy*, **43(7)**:1709-1714.

Mill, F.V. 2005, Drug-related Problems: A Cornerstone for Pharmaceutical Care, *Journal of the Malta College of Pharmacy Practice*, **10**.

Monks, T.J., Smith, R.L. and Caldwell, J. 1981, A metabolic and pharmacokinetic comparison of theophylline and aminophylline (theophylline ethylenediamine), *Journal of Pharmacy and Pharmacology*, **33(2)**:93-7.

Montoliu, J., Almirall, J., Ponz, E., Campistol, J.M., Revert, L. 1990, Treatment of hyperkalaemia in renal failure with salbutamol inhalation. *J Intern Med*, **228(1)**:35-7.

Morgan, D.J., Paull, J.D., Richmond, B.H., Wilson—Evered, E. and Ziccone, S.P. 1986, Pharmacokinetics of Intravenous and Oral Salbutamol and Its Sulphate Conjugat, *British Journal of Clinical Pharmacy*, **22**:587-593.

Morrow, T.J. 2007, Implications of Pharmacogenomics in the Current and Future Treatment of Asthma, *Journal of Managed Care Pharmacy*, **13(6)**:497-505.

Muhammad, H.A., Abdulfttah, M.T., Abdulazez, A.O., Mahmoud, A.M., Emam, R.M. 2014, A study of electrolyte disturbances in patients with chronic stable asthma and with asthma attacks, *Egyptian Journal of Chest Diseases and Tuberculosis*, **63(3)**:529–534.

Mulrennan, S., Wright, C., Thompson, R., Goustas, P., Morice, A. 2004. Effect of Salbutamol on Smoking Related Cough, *Pulm Pharmacol Ther*, **17(3)**:127-131.

Munro, A. and Jacobs, M. 2004, Is intravenous aminophylline better than intravenous salbutamol in the treatment of moderate to severe asthma?, *Emerg Med J*, **21**:78-80.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Nabi H, Kivimaki M, Batty GD, *et al*., 2013, Increased Risk of Coronary Heart Disease Among Individual Reporting Adverse Impact of Stress on Their Health: The Whitehall II Prospective Cohort Study, *European Heart Journal*, **34(34)**:2697-2705.

Nagata, K., Ishitobi, K., Yamamoto, Y., Ikeda, T., Hori, S., Matsumoto, Y., Sasaki, T. 1997, Increased theophylline metabolism in the menstrual phase of healthy women, *Journal of Allergy and Clinical Immunology*, **100(1)**:39-43.

Naing, L., Win, T., Rusli, B.N. 2008, Medical Statistic: Practical Issues in Calculating the Sample Size for Prevence Studies, *Archives of Orofacial Sciences* 2006; **1**:9-14.

Nakamura, A., Imaizumi, A., Yanagawa, Y. 2004, Beta 2-adrenoceptor function in the kidney, *Nihon Yakurigaku Zasshi*, **124(6)**:427-34.

Nakamura, A., Niimi, R., Imaizumi, A., Yanagawa, Y. 2007, Renal effects of beta2-adrenoceptor agonist and the clinical analysis in children, *Pediatr Res*, **61(1)**:129-33.

Nakano, J., Yano, T., Yamamura, K., Yoshihara, H., Ohbayashi, O. And Yamashita N, *et al*. 2006, Aminophilline suppress the release of chemical mediators in treatment of acute asthma, *Respiratory Medicine*, **100(3)**:542-50.

Nakura, H., Tateishi, T., Watanabe, M., Asoh, M., 1998, *Effect of Hypoalbuminemia on The Disposition of Theophylline: Comparative Study with Sprague-Dawley Rats and a Mutant Sprague-Dawley Hyperlipidemic Strain with Hypoalbuminemia*, Drug Metabolism and Disposition. The American Society for Pharmacology and Experimental Therapeutics.

Namazi, S., Vessal, Gh., Hooshmand, Sh., Ostovan, M., A. and Mehrpuor, Z. 2010, A Drug Utilization Research on Aminophylline/Theophylline in Ali-Asghar Hospital, Shiraz, Southern Iran, *Iranian Red Crescent Medical Journal* (IRCMJ), **12(2)**:181-186.

Naranjo, C.A., Buston, U., Sellers, E.M., Sandor, P., Ruiz, I. and Roberts, E.A., *et al*. 1981, A Method of Assessing the Probability of Adverse Drug Reactions, *Clinical Pharmacology and Therapeutics*, **30**:239-45.

Narayanan, S. 2000, The Preanalytic Phase: An Important Component of Laboratory Medicine, *American Journal of Clinical Pathology*, **113**:429-452.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

National Center for Chronic Disease Prevention and Health Promotion. 2011, *Data Source with Asthma Content: Behavioral Risk Factor Surveillance System (BRFSS)*.

National Institute of Allergy and Infectious Diseases. 2003, *Monitoring and Reporting Adverse Events. Guidance - NIAID Clinical Terms of Award*, ICH Expedited Reporting.

National Asthma Education and Prevention Program. 2007, *Guidelines for the diagnosis and management of asthma, Expert Panel Report 3*, Maryland: National Institutes of Health, National Heart, Lung, and Blood Institute.

National Institutes of Health. 2009, *Pharmacokinetic study of Oseltamivir and Intravenous Zanamivir, Section 8: Laboratory Considerations Version 1.0*, pp1-11.

National Kidney Foundation, 2014. A Clinical Update on Gout: Optimizing Care for Patients with Chronic Kidney Disease. National Kidney Foundation, Inc. 02-10-6446_ABE.p.1-6.

Newnham, D.M. 2001, Asthma medications and their potential adverse effects in the elderly: recommendations for prescribing. *Drug Safety:An International Journal Of Medical Toxicology And Drug Experience*, **24(14)**:1065-1080.

Nievas IFF, Anand KJS. 2013, Severe Acute Asthma Exacerbation in Children: A Stepwise Approach for Escalating Therapy in a Pediatric Intensive Care Unit, *J Pediatr Pharmacol Ther*, **18(2)**:88–104.

Nicot, G., Charmes, J.P., Lachatre, G., Sautereau, D. *et al*. 1989, Theophylline toxicity risks and chronic renal failure, *Int J Clin Pharmacol Ther Toxicol*, **27(8)**:398-401.

Nuriah, D. 2012, Pemantauan DRPs pada Pasien Asma Akut di IGD di RSUD Dr. R.Soedarsono Pasuruan Selama Periode Bulan Februari-Maret 2012, *Skripsi*, S.Farm., Fakultas Farmasi Universitas Surabaya, Surabaya.

Nottinhham Univerity Hospital-NHS. *Guidelines for performing physiological observations*. 2011. NHS Trust. P1-53

Obase, Y., Shimoda, T., Kawano, T., Saeki, S., Tomari, S.Y. and Mitsuta-Izaki, K., *et al*. 2003, Polymorphisms in the CYP1A2 gene and theophylline metabolism in patients with asthma, *Clinical Pharmacology and Therapeutics*, **73(5)**:468-74.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Oberg, K.C. 1999, Adverse Drug Reactions, *American Journal of Pharmaceutical Education*, **63**:199-204.

Odunayo, A. 2014, Management of Potassium Disorders, Clinician's Brief (online), **2 August 2016,** <http://www.cliniciansbrief.com/sites/default/files/attachments/Management%20of%20Potassium%20Disorders.pdf>.

Ogedegbe, G., Pickering, T. 2010, Principle and Techniques of Blood Pressure Measurement, *Cardiol Clin*, **28(4)**:571-586.

Oemiati, R., 2013. Kajian Epidemiologis Penyakit Paru Obstruktif Kronik (PPOK). Media Litbangkes Vol. 23 No. 2, Juni 2013: 82-88 82.

Ohta, K., Yamashita, N., 1999, Apoptosis of Eosinophils and Lymphocytes in Allergic Inflammation, *j Allergy Clin Immunol*, **104(1)**:14-21.

Ohta, K., Fukuchi, Y., Grouse, L., Mizutani, R., Rabe, K.F., Rennard, S.I., Zhong, N. 2004, A Prospective Clinical Study of Theophylline Safety in 3810 Elderly with Asthma or COPD, *Respiratory Medicine*, **98**:1016-1024.

Okuyucu, E.E., Guven, O., Ucar, E., Duman, T. 2014, Assessment of Headache in Men Taking Phosphodiesterase-5 Inhibitor (Tadalafil) for Erectile Dysfunction, *Acta Medica Mediterranea*, **30**:1007-1011.

Ou-Yang, D.S., Huang, S.L., Wang, W., Xie, H.G., Xu, Z.H. and Shu, Y., *et al*. 2000, Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population, *British Journal of Clinical Pharmacology*, **49**:145–151.

Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., Santonastaso, M. 2009, CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. *J Hypertension*, **27(8):**1594-1601.

Panda, U.N. (ed.). 2002, Current Medical Diagnosis and Treatment. 3rd ed. Jaypee Brother Medical Publishers (P) Ltd., India. p.975.

Parameswaran, K., Belda, J., Rowe, B.H. 2000, Addition of intravenous aminophylline to beta2-agonists in adults with acute asthma, *Cochrane Database Syst Rev.*, **4**:CD002742.

Paredi, P., Barnes, P.J. 2008, The airway vasculature: recent advances and clinical implications, Thorax, **64**:444–450.

UNIVERSITAS GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

PDPI (Perhimpunan Dokter Paru Indonesia). 2003, PPOK (Penyakit Paru obstruksi Kronik). Pedoman Praktis Diagnosis dan Penatal aksanaan di Indonesia. P.23.

Pesce, A.J., Rashkin, M. and Kotagal, U. 1998, Standards of laboratory practice: theophylline and caffeine monitoring, *Clinical Chemistry*, **44(5)**:1124–1128.

PHARMAC. 2004, *A Prescription For Pharmacoeconomic Analysis*, Version 1.1, *Pharmaceutical Management Agency Ltd*.

Primatesta, P., Falaschetti, E., Gupta, S., Marmot, M.G., Poulter, N.R. 2001, Association Between Smoking and Blood Pressure: Evidence From the Health Survey for England, *Hypertension*, **37**:187-193.

Prest, M.S., Kristianto, F.C. and Tan, C.K. 2003, Reaksi Obat yang Tidak Dikehendaki, in Aslam, M., Tan, C.K. and Prayitno, A. (eds.). *Farmasi Klinis: Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien*. PT Elex Media Komputindo, Jakarta, pp 101-107.

Pugsley, M.K., Authier, S. and Curtis, M.J. 2008, Principles of Safety Pharmacology, British Journal of Pharmacology. **154(7)**: 1382–1399

Queljoe, D.D., Wahjudi, M., Erdiansyah, M., Suryadinata, R.V., Lorensia, A., 2014, Studi Pendahuluan Polimorfisme Genetik Gen CYP1A2*1F pada Pasien Asma dan Non-Asma di Indonesia, *Indonesia journal of Clinical Pharmacy* (IJCP), **4(1)**:8-16.

Rachaiah J, Rachaiah N, 2013, Unusual cause of hypokalemia and paralysis in an elderly patient with Bronchial Asthma, *International Journal of Medical Science and Public Health*, **2(4)**:1114-1116.

Raftery, J. 2001, NICE: faster access to modern treatments? Analysis of guidance on health technologies, *British Medical Journal*, **323**:1300-1303.

Rahayu, A.H. 2009, Analisa Drug Related Problems pada Penderita Asma Usia Dewasa di Rumah Sakit Delta Surya Sidoarjo selama Juni 2008- April 2009, *Skripsi*, S.Farm., Fakultas Farmasi Universitas Surabaya, Surabaya.

Rasmussen, B.B., Brosen, K. 1996, Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans, *Ther Drug Monit*,**18(3)**:254-62.

Remington, J.P, Beringer, P. 2006, *Remington: The Science And Practice Of Pharmacy*, 21th edition, Lippincott Williams & Wilkins, Philadelphia. US. pp 1372.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Roberts, G., Newsom, D., Gomez, K., Raffles, A., Saglani, S. and Begent, J. 2003, Intravenous salbutamol bolus compared with an aminophylline infusion in children with severe asthma: a randomised controlled trial, *Thorax*, **58**:306–310.

Rodrigo, G.J. 2007, There Are No Excuses for Not Performing Spirometry in Acute Asthmatics in the Emergency Department Setting, *CHEST*, **131(5)**:1615.

Royal Pharmaceutical Society. 2013, *British National Formulary* (BNF) 66, Pharmaceutical Press. UK.

Sachse, C., Brockmöller, J., Bauer, S., Roots, I. 1999, Functional significance of the C→A polymorphism in intron I of the cytochrome P450 *CYP1A2* gene tested with caffein,.*Br J Clin Pharmacol*., **47**:445–449.

Sahan M.,Yılmaz M., Gokel Y, Erden ES., Karakus A. 2013, Nebulized salbutamol for asthma: Effects on serum potassium and phosphate levels at the 60 min - Review Port Pneumol, *Sociedade Portuguesa de Pneumologia*, **19(5)**:200-203.

Salamzadeh, J., Dadashzadeh, S., Habibi, M. and Estifaie, S. 2008, Serum and Saliva Theophylline Levels in Adult Outpatients with Asthma and Chronic Obstructive Pulmonary Disease (COPD): A Cross-Sectional Study, *Iranian Journal of Pharmaceutical Research*, **7(1)**:83-87.

Salpeter, S.R., Ormiston, T.M., Salpeter, E.E. 2004, Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis, *CHEST*, **125(6)**:2309-21.

Sanchez, L.A. 2008, Pharmacoeconomic : Principles, Methods and Applications, in DiPiro, J., Talbert, R., Yee, G., Matzke, G., Wells, B. and Posey, M., editors. *Pharmacotherapy: A Pathophysiologic* Approach, 7th edition, McGrawHill, New York. US.

SAS Institute Inc. 2008, SAS/STAT® 9.2 User's Guide. Cary, NC: SAS Institute Inc.

Scratcherd T, Case RM. 1990. The role of cyclic adenosine-3', 5 -monophosphate (AMP) in gastrointestinal secretion, *GUT*, **10**:957-961.

Schulz, M., Verheyen, F., Muhlig, S., Muller, J.M., Muhlbauer, K. and Knop-Schneickert, E. *et al*. 2001, Pharmaceutical care services for asthma patients: a controlled intervention study, *The Jornal of Clinical Pharmacology*, **41**:668-76.

UNIVERSITAS GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Scottish Intercollegiate Guidelines Network. 2011, *British Guideline on the Management of Asthma*, British Thoracic Society. UK.

Self, T.H., Abou-Shala, N., Burns, R., *et al*. 1990, Inhaled Albuterol and Oral Prednisone Therapy in Hospitalized Adult Asthmatics, *Does Aminophylline Add Any Benefit?*, *CHEST*, **98**:13-17-21.

Self, T.H., Chrisman, C.R. and Finch, C.K. 2008, Asthma, in Koda-Kimble, M. A., Young, L.Y., Kradjan, W.A., Guglielmo, B.J., Alldredge, B.K. and Corelli, R.L. *Applied Therapeutics – The Clinical Use of Drugs*, 9th edition, Lippincort Williams&Wilkins, Philadelphia. US.

Shargel, L., Wu-Pong, S. and Andrew, B.C. 2012, *Applied Biopharmaceutics & Pharmacokinetics*, 6th edition, McGraw-Hill, New York. US.

Shastry, B.S. 2006, Pharmacogenetics and the concept of individualized medicine, *The Pharmacogenomics Journal*, **6**:16–21.

Shen, J., Johnston, M. and Hays, R.D. 2011, Asthma Outcome Measures: Asthma Exacerbation, Expert *Review of Pharmacoeconomics & Outcomes Research*, **11(4)**:447-453.

Shindo, K., Matsumoto, Y., Sumitomo, M., Matsumura, M., Okubo, T., 1991, Measurement of leukotriene C4 and D4 in arterial blood of asthmatic patients during remission, *Ann Allergy*, **66(5)**:405-10.

Shu, Y., Cheng, Z.N., Liu, Z.Q., Wang, L.S., Zhu B. and Huang, S.L., *et al.* 2001, Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects, *Acta pharmacologica Sinica*, **22**:283-8.

Silverman, R.A., Flaster, E., Enright, P.L., Simonson, S.G. 2007, FEV1 performance among patients with acute asthma: results from a multicenter clinical trial, *CHEST*, **131(1)**:164-71.

Singh, A.S., Masuku, M.B. 2014. Sampling Techniques & Determination of Sample Size in Applied Statistics Research: An Overview, *International Journal of Economics, Commerce and Management*, **2(11)**:1-22.

Siroux, V., Pin, I., Oryszczyn, M.P., Moual, N.L., Kauffmann, F. 2000, Relationships of active smoking to asthma and asthma severity in the EGEA study, *Eur Resp Jour*, **15**:470-77.

Skrepnek, G.H. 2005, *Cost-Effectiveness Analysis (CEA) in Principles of Pharmacoeconomic*, 3 th edition, Harvey Whitney Books Company, USA.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Smellie, W., Heald, A. 2007, Hyponatraemia and hypernatraemia: pitfalls in testing. BMJ, **334(7591)**:473.

SNPedia. 2016, rs762551. **2 August 2016,** <https://www.snpedia.com/index.php/Rs762551 >.

Sohn, K. 2015, The Height Premium in Indonesia, *Economics & Human Biology*, **16**:1-15.

Sree, N.K., Rao, R.N. 2011, Salbutamol Nebulization in The Treatment of Hyperkalemia, *International Journal of Pharma and Bio Sciences*, **2(4)**:104-118.

Srinivasan, R. and Ramya, G. 2011, Adverse Drug Reaction-Causality Assessment, *International Journal of Research in Pharmacy and Chemistry*, **1(3)**:606-612.

Sotandyo N, 2007, Nutrisi pada Pasien Kanker yang Mendapatkan Kemoterapi, *Indonesian Journal of Cancer*, **4**:144-148

Sweetman, S.C., (ed.). 2009, *Martindale*: *The Complete Drug Reference*, 36th edition, Pharmaceutical Press. UK.

Subekti T, 2011, Metode Relaksasi untuk Menurunkan Stres dan Keluhan Tukak Lambung pada Penderita Tukak Lambung Kronis, *Jurnal Psikologi*, **38(2)**: 147-163.

Tsujimoto, M., Sugimoto, S., Nagatomo, M., Furukubo, T., Izumi, S., Yamakawa, T., Minegaki, T., Nishiguchi, K. 2014, Possibility of decrease in CYP1A2 function in patients with end-stage renal disease, *Ther Apher Dial*., **18(2)**:174-80.

Tan, K.S., McFarlane, L.C., Lipworth, B.J., 1998, Beta2-adrenoceptor regulation and function in female asthmatic patients receiving the oral combined contraceptive pi ll, *CHEST*, **113(2)**:278-82.

Takata, K., Saruwatari, J., Nakada, N., Nakagawa, M., Fukuda, K. and Tanaka, F., *et al*. 2006, Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy, *European Journal of Clinical Pharmacology*, **62(1)**:23-8.

Tarloff, J.B. 2012, *Severity of Adverse Drug Reactions*, Merck Manual, Merck Sharp & Dohme Corp, **1 January 2013,** <http://www.merckmanuals.com/home/drugs/adverse_drug_reactions/severity_of_adverse_drug_reactions.html>.

UNIVERSITAS GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Thapa, B.R., Walia, A. 2007, Symposium: Newer Diagnostic Tests: Liver Function Tests and their Interpretation, *Indian Journal of Pediatrics*, **74(7)**:663—671.

Tilley, S.L. 2011, Methylxanthines in asthma, *Handbook of Experimental Pharmacology*, **200**:439-56.

Tobin A, 2005, Intravenous Salbutamol: Too Much of a Good Thing – Special Review, *Critical Care and Resuscitation*, **7**:119-127.

Travers, A.H., Rowe, B.H., Barker, S., Jones, A., and Camargo, C.A. 2002, The Effectiveness of IV B-Agonists in Treating Patients With Acute Asthma in the Emergency Department: A Meta-analysis, *CHEST*, **122**:1200-1207.

Travers, A.H., Jones, A.P., Camargo, C.A., Milan, S.J. and Rowe, B.H. 2012, Intravenous beta(2)-agonists versus intravenous aminophylline for acute asthma, *Cochrane Database Syst Rev*, **12**:CD010256.

Tse, S.M., Tantisira, K. and Weiss, S.T. 2011, The Pharmacogenetics and Pharmacogenomics of Asthma Therapy, *Pharmacogenomics Journal*, **11(6)**:383-392.

Tsujimoto, N., Saraya, T., Nunokawa, H., Ohkuma, K. 2015, Flapping Tremor as a Diagnostic Tool for Evaluation of Hypercapnia, *Pulm Res Respir Med Open J*, **2(1)**:49-51.

Tyagi, N., Gulati, K., Vijayan, V.K. and Ray, A. 2008, A Study to Monitor Adverse Drug Reactions in Patients of Chronic Obstructive Pulmonary Disease: Focus on Theophylline, *The Indian Journal of Chest Diseases & Allied Sciences*, **50**:199-202.

Umeda, M., Ichiyama, T., Hasegawa, S., Kaneko, M., Matsubara, T., Furukawa, S., 2002, Theophylline inhibits NF-kappaB activation in human peripheral blood mononuclear cells, *Int Arch Allergy Immunol*, **128(2)**:130-5.

Upadhyay, R., Kalla, A. 2011, *Asymptomatic Elevation of Transaminases*, Medicine Update-2011.p 354-357.

Uslu, A., Ogus, C., Ozdemir, T., Bilgen, T., Tosun, O. and Keser, I. 2010, The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients, *Biochemistry and Molecular Biology reports*, **43(8)**:530-534.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Valderas, J.M., Starfield, B., Sibbald, B., Salisbury, C., *et al*. 2009, Defining Comorbidity: Implications for Understanding Health and Health Services, *The Annals of Family Medicine*, **7(4)**: 357–363.

Walley, T. and Davey, P. 1995, Pharmacoeconomics: a challenge for clinical pharmacologists, *British Journal of Clinical Pharmacology*, **40**:199-202.

Walley, T. and Haycox, A. 1997, Pharmacoeconomics: basic concepts and terminology, *British Journal of Clinical Pharmacology*, **43**:343–348.

Walley, T., Haycox, A. and Boland, A. 2004, *Pharmacoeconomics*, Elsevier Science Limited. UK.

Wang, C.H., Lin, H.C., Lin, C.H., Yu, C.T., Liu, S.L.,Hunag, K.H, 2003, Effect of theophylline and specific phosphodiesterase IV inhibition on proliferation and apoptosis of progenitor cells in bronchial asthma, *British Journal of Pharmacology*, **138**:1147–1155

Ward, M., Langton, J.A. 2010, Blood Pressure Measurement, *Contin Educ Anaesth Crit Care Pain*, **7(4)**:122-126.

Weinberger, M. and Hendeles, L. 1996, Theophylline In Asthma, *The New England Journal of Medicine*, **334(21)**:1380-1388.

Wheeler, D.S. Jacobs, B.R., Kenreigh, C.A., Bean. J.A., Hutson, T.K., Brilli, R.J. 2005, Theophylline versus terbutaline in treating critically ill children with status asthmaticus: a prospective, randomized, controlled trial, *Pediatr Crit Care Med*, **6(2)**:142-7.

Xu, Y.J. 2004, Development of theophylline in treatment of Asthma and Chronic Obstructive Pulmonary Disease, *Zhongguo Yi Xue Ke Xue Yuan Xue Bao*, **26(3)**:319-22.

Xu, K., Xu, Y.H., Chen, J.F. Schwarzschild, M.A. 2010, Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's diseas, *Neuroscience*, **167(2)**:475-81.

Yasuda, S.U., Zhang, L., Huang, S.M. 2008, The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies, *Clinical Pharmacology & Therapeutics*, **84(3)**:417-423.

Yao, P.L., Tsai, M.F., Lin, Y.C., Wang, C.H., Liao, W.Y. and Chen, J.J.W., *et al*. 2005, Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation, *Respiratory Research*, **6**:89.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/

Yasui, K., Agematsu, K., Shinozaki, K., Hokibara, S., Nagumo, H. and Nakazawa, T., *et* al. 2000, Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism, *Journal of Leukocyte Biology*, **67(4)**:529-535.

Yim, E.Y., Kang, H.R., Jung, J.W., Sohn, S.W., *et al*., 2013, CYP1A2 polymorphism and theophylline clearance in Korean non-smoking asthmatics, *Asia Pac Allergy*, **3**:231-240

Yoon, Y., Park, H.D., Park, K.U., Kim, J.Q., Chang, Y.S. and Song, J. 2006, Associations between CYP2E1 promoter polymorphisms and plasma 1,3-dimethyluric acid/theophylline ratios, *European Journal of Clinical Pharmacology*, **62(8)**:627-31.

Yue, Q.Y., Svensson, J.O., Alm, C., Sjoqvist, F., Sawe, J. 1989, Interindividual and Interethnic differences in the Demethylation and Glucuronidation of Codeine, *British Journal of Clinical Pharmacology*, **28**:629-637.

Zaki, S.A. 2011, Adverse drug reaction and causality assessment scales, Lung India, **28(2)**:152–153.

Zhou, H.H., Koshakji, R.P., Silberstein, D.J., Wilkinson, G.R., Wood, A.J.J. 1989, Racial Differences in Drug Response: Altered Sensitivity to and Clearance of Propranolol in Men of Chinese Descent as Compared with American Whites, *New England Journal of Medicine*, **320**:565-570.

Zhou, H.H., Sheller, J.R., Wood, M., Wood, A.J. 1990, Caucasians are more sensitive than Chinese to the Cardiovascular and Respiratory effects of Morhipne but Less to The Gastrointestinal Side Effects, *Clinical Research*, **38**:968A.

UNIVERSITAS
GADJAH MADA
ANALISIS PERBANDINGAN RISIKO DAN MANFAAT (RISK-BENEFIT ASSESSMENT) PENGGUNAAN AMINOFILIN DAN SALBUTAMOL PADA EKSASERBASI ASMA
AMELIA LORENSIA, Prof. Dr. Zullies Ikawati,Apt.
Universitas Gadjah Mada, 2016 | Diunduh dari http://etd.repository.ugm.ac.id/